ОЦЕНКА ВЛИЯНИЯ ПОЧЕЧНЫХ ФАКТОРОВ РИСКА НА ВЕРОЯТНОСТЬ РАЗВИТИЯ РЕЦИДИВА СТЕНОКАРДИИ У БОЛЬНЫХ, ПОДВЕРГШИХСЯ РЕВАСКУЛЯРИЗАЦИИ МИОКАРДА, ОПТИМИЗАЦИЯ МЕДИКАМЕНТОЗНОЙ ТЕРАПИИ

The aim of the study was to estimate the impact of renal risk factors (RRF), as well as drug therapy in patients with coronary heart disease and indication for revascularization in the risk of recurrence of angina pectoris. 90 patients with coronary heart disease and indications for the restoration of coronary blood flow were surveyed. The high prevalence of renal risk factors among the patients examined was established. It was revealed that within increase in the maximum risk of recurrence of stenosis of CA the risk of the development of angina pectoris after coronary revascularization is increasing, and with the presence of renal risk factors (microalbuminuria, β2-microglobulinuria, and chronic kidney disease), there is an additional increase in the risk of recurrence of angina pectoris. The analysis of the data demonstrated a significant reduction in risk of recurrence of angina pectoris with the ACE inhibitors and metoprolol tartrate prescription before myocardial revascularization.

1. Арутюнов Г.П., Оганезова Л.Г. β-адреноблокаторы: влияние на тубулоинтерстициальную ткань, натрийурез и почечную функцию в целом // Сердце. 2011. Т. 10, № 6 (62). С. 343–348.

2. Нефрология: национальное руководство / Под ред. Н.А. Мухина. М.: ГЭОТАР-Медиа, 2009. 720 с.

3. Тепляков А.Т. и др. Рецидивы стенокардии после стентирования коронарных артерий: влияние дислипидемии // Бюллетень СО РАМН. 2006. Т. 119, № 1. С. 13–18.

4. Шульженко Л.В. и др. Кардиоренальные синдромы в инвазивной кардиологии. Отдаленные исходы избирательных коронарных интервенций у больных с коронарным атеросклерозом и хронической болезнью почек // Международный журнал интервенционной кардиоангиологии. 2010. № 20. С. 41–46.

5. Chan A.Y.M. et al. Effect of β-blocker use on outcomes after discharge in patients who underwent cardiac surgery // J. Thorac. Cardiovasc. Surg. 2010. № 140. Р. 182–187.

6. Coresh J. et al. Prevalence of Chronic Kidney Disease in the United States // JAMA. 2007. Vol. 17, № 298. Р. 2038–2047.

7. Ellis S.G. et al. Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting // American Journal of Cardiology. 2002. Vol. 89, № 8. P. 937–940.

8. Guidelines on myocardial revascularization. 2010 // European Heart Journal. 2010. № 31. С. 2501–2555.

9. Hage F.G. et al. The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease // J. Am. Coll. Cardiol. 2009. № 53. P. 2129–2140.

10. Kawai K. et al. Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging // American Journal of Cardiology. 2004. Vol. 93, № 6. P. 719–723.

11. Lazar H.L. All Coronary Artery Bypass Graft Surgery Patients Will Benefit From Angiotensin-Converting Enzyme Inhibitors // Circulation. 2008. № 117. P. 6–8.

12. Levey A.S. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. 2005. Vol. 6, № 67. P. 2089–2100.

13. Lopes N.H. et al. Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease // The Journal of Thoracic and Cardiovascular Surgery. 2009. Vol. 137, № 6. P. 1443–1449.

14. Odden M.C. et al. The Impact of the Aging Population on Coronary Heart Disease in the United States // American Journal of Medicine. 2011. Vol. 9, № 124. P. 827–833.

15. Prentice R. et al. Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by indepth plasma proteome profiling // Genome Medicine. 2010. Vol. 2, № 7. P. 48.

16. Ronco C., Haapio M., House A.A. et al. Cardiorenal Syndrome // J. Am. Coll. Cardiol. 2008. Vol. 52. P. 1527–1539.

17. Saijo Y. et al. Relationship of beta2-microglobulin to arterial stiffness in Japanese subjects // Hypertens Res. 2005. Vol. 6. № 28. P. 505–511.

18. Wilson A.M. et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies // Circulation. 2007. Vol. 12, № 116. P. 1396–1403.